Seres Therapeutics
MCRB
93 hedge funds and large institutions have $50M invested in Seres Therapeutics in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 25 increasing their positions, 27 reducing their positions, and 27 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.56% less ownership
Funds ownership: 2.84% → 2.28% (-0.56%)
7% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 27
6% less funds holding
Funds holding: 99 → 93 (-6)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
25% less capital invested
Capital invested by funds: $66.8M → $50M (-$16.7M)
33% less call options, than puts
Call options by funds: $319K | Put options by funds: $478K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.25M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$661K |
| 3 |
Millennium Management
New York
|
+$626K |
| 4 |
Jane Street
New York
|
+$518K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$262K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.22M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3.69M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.58M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.34M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.29M |
MCRB Hedge Fund Activity: Q2 2024 in Review
93 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2024, worth a combined $50M — down 25% from $66.8M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MCRB and 21 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 25 added.
The largest buyer was Tang Capital Management, adding an estimated $1.25M. The largest seller was BlackRock, cutting an estimated $4.22M.
- 93 institutional investors held Seres Therapeutics (MCRB) as of Q2 2024, down from 99 in Q1 2024.
- Funds reported $50M of Seres Therapeutics stock for Q2 2024, down 25% quarter-over-quarter.
- 21 funds opened new Seres Therapeutics positions in Q2 2024 and 27 closed out, a net change of -6 holders.
- The largest Seres Therapeutics buyer in Q2 2024 was Tang Capital Management, an estimated $1.25M added.
- The largest Seres Therapeutics seller in Q2 2024 was BlackRock, an estimated $4.22M sold.
Based on aggregated 13F filings for Q2 2024.